Green On The Go licensed cannabis delivery logo
← The Green Room

Myrcene Effects: One Driving Study Raises an Impairment Concern

October 8, 2026

Myrcene Effects: One Driving Study Raises an Impairment Concern

Myrcene Effects: One Driving Study Raises an Impairment Concern

Myrcene article title card with botanical sketches

Myrcene is a common cannabis terpene most often linked to relaxation, analgesia, and anti-inflammatory effects, but the strongest evidence for these claims comes from animal and in vitro studies, while human data remain limited to small pilot trials. A 2023 driving-simulator study adds a practical caution: pure myrcene measurably affected attention and speed control in healthy volunteers. That gap between preclinical promise and thin human data should shape how seriously you take any specific claim about this terpene.

TL;DR:

  • Check the batch specific certificate of analysis, because genetics, growing conditions, curing, and lab methods can shift myrcene levels even within one strain.
  • The driving trial tested 15 milligrams of pure myrcene in 10 volunteers, so its results do not establish impairment at every consumer dose.
  • Avoid combining high myrcene products with alcohol, benzodiazepines, or opioids, and ask a clinician about prescription drugs metabolized by CYP enzymes.
  • Edibles may take 30 to 120 minutes to take effect, while inhaled products act within minutes; avoid driving after trying a new product.
  • Rodent tumor findings came from oral doses far above typical human exposure, and toxicologists consider some observed kidney mechanisms poorly predictive of human risk.
Greenonthegodelivery
Choose Cannabis with Clear Lab Results
Explore Green On The Go’s curated cannabis menu, with lab-tested products from a legal supply chain and verifiable results.
Visit Green On The Go

Table of Contents

What Myrcene Is and How Common It Is in Cannabis

Beta-myrcene is a monoterpene, a small, oil-soluble molecule that gives many plants their characteristic aroma. It shows up across the plant kingdom, not just in cannabis: hops, lemongrass, mangoes, and thyme all produce it in meaningful amounts, which is part of why it smells vaguely earthy, musky, and fruity depending on the source.

In cannabis specifically, myrcene is frequently the dominant or co-dominant terpene in commercial flower products. Lab surveys cited in a comprehensive review of myrcene’s biological profile report that myrcene often makes up more than 20% of the total terpene fraction in tested samples, making it one of the most prevalent terpenes in modern cultivars.

A few practical points help explain why the number on a given package can vary so much from the next:

  • Genetics drive the baseline. Some cultivars are bred or selected specifically for myrcene-heavy terpene profiles, which is why certain strains are marketed as higher in this compound than others.
  • Growing conditions shift the total. Light exposure, curing time, and harvest timing all affect how much terpene content survives into the final dried product.
  • Lab methodology matters. Certificates of Analysis (COAs) report terpene content either as milligrams per gram or as a percentage by weight, and the extraction method a lab uses can produce slightly different readings even from the same batch.
  • Batch-to-batch variability is real. Two bags of the same strain name grown in different rounds can have meaningfully different terpene totals, which is why checking the COA for your specific batch matters more than trusting the strain name alone.

Understanding this baseline matters because almost every claim about what myrcene “does” assumes a certain level of exposure, and that level is far from fixed across products.

Reported Physiological Effects: Sedation, Pain, Inflammation, and More

Myrcene has accumulated a long list of reported effects in the scientific literature, but the evidence behind each claim sits at a different level of confidence. Treating “sedative,” “analgesic,” and “anti-inflammatory” as equally well-established would overstate what the research actually supports.

The clearest way to think about this is evidence level, not just effect name:

  • Sedation and relaxation: supported mainly by rodent studies showing prolonged sleep time with barbiturates, plus one small human inhalation study reporting subjective relaxation.
  • Analgesia (pain relief): supported by multiple rodent pain models, with a specific mechanistic link to opioid pathways.
  • Anti-inflammatory activity: supported by in vitro and animal models showing reduced inflammatory markers.
  • Antioxidant activity: supported mostly by in vitro assays measuring antioxidant enzyme activity.
  • Anticonvulsant effects: reported occasionally in animal models, with no confirmatory human data.
  • Anxiolytic (anxiety-reducing) effects: suggested by some animal behavior studies and consumer reports, but not established in controlled human trials.

The analgesic findings are among the more mechanistically interesting. According to the same review of myrcene’s health effects, rodent studies found that myrcene’s pain-relieving effect was partially reversed by naloxone, a drug that blocks opioid receptors, and by yohimbine, which blocks certain noradrenergic receptors. That pattern suggests myrcene’s analgesic action in rodents works at least partly through the body’s own opioid and noradrenergic signaling systems, rather than through the cannabinoid receptors that THC acts on. It is a notable finding, but it comes from animal models and has not been confirmed in controlled human pain trials.

Myrcene often represents a large portion of the total terpene content in commercial cannabis samples, according to lab survey data summarized in the Frontiers review, which helps explain why it is the terpene most frequently implicated in strain-specific effect claims, even though the clinical research behind those claims is still thin.

The anti-inflammatory and antioxidant evidence follows a similar pattern. In vitro work has shown reduced levels of inflammatory markers like PGE2 and IL-1β when cells are exposed to myrcene, and some animal models show measurable antioxidant enzyme increases. These are legitimate signals worth further study, but in vitro and rodent findings do not automatically translate into a predictable effect in a person vaping or smoking a myrcene-rich flower. The step from “reduces inflammatory markers in a petri dish” to “will reduce your joint pain” involves absorption, metabolism, and dosing variables that have not been mapped out in humans.

Anticonvulsant activity appears in some of the animal literature as well, but it is one of the least replicated effects and has essentially no human trial data behind it. If you see anticonvulsant benefits mentioned in casual cannabis content, understand that claim rests on a narrower and older evidence base than the analgesic or anti-inflammatory findings.

The sedative and relaxation effects, which are probably the most commonly cited reason people seek out high-myrcene products, sit in an interesting middle ground. Rodent studies showing prolonged barbiturate sleep time are suggestive of a real central nervous system effect, and a small human inhalation study (discussed in more detail in the next section) reported EEG changes consistent with relaxation. But “small” here means a handful of participants, not a validated clinical trial, so the honest summary is that sedation is plausible and biologically grounded, not proven at typical consumer exposure levels.

Mechanisms of Action: Pharmacology and Plausible Targets

The honest answer to “how does myrcene actually work” is that researchers have identified several plausible biological targets, but no single confirmed mechanism explains all of its reported effects. That is typical for a small lipophilic molecule that interacts with multiple systems at once rather than one specific receptor.

A few mechanistic threads run through the current research:

  • TRP channel interaction. Myrcene has been studied for activity at transient receptor potential (TRP) channels, which are involved in pain signaling and temperature sensation, though findings have not replicated consistently across species or study designs.
  • Opioid and noradrenergic pathways. As noted above, naloxone and yohimbine reversal experiments in rodents point to endogenous opioid and noradrenergic system involvement in myrcene’s analgesic effects, rather than a THC-like cannabinoid receptor mechanism.
  • CYP enzyme interaction. Myrcene appears to interact with cytochrome P450 (CYP) enzymes, the liver enzyme family responsible for metabolizing a large share of prescription drugs, which raises the possibility of altered drug metabolism when myrcene is consumed alongside certain medications.
  • Lipophilicity and blood-brain barrier crossing. As a small, fat-soluble molecule, myrcene crosses biological membranes easily, including the blood-brain barrier, which gives a plausible biological basis for the central nervous system effects reported in sedation and relaxation studies.

The CYP enzyme angle deserves particular attention for anyone combining cannabis with other medications. Rodent data summarized in the Frontiers review on myrcene’s biological profile showed that myrcene prolonged barbiturate-induced sleep time, a finding consistent with either a pharmacodynamic additive effect, a metabolic interaction that slows drug clearance, or both. Regulators and toxicologists flag this as a reason for caution when combining myrcene-rich cannabis products with other sedating substances, since the practical result could be stronger or longer sedation than either substance alone would produce.

It is worth being direct about the limits here: most of the mechanistic work described above comes from rodent or in vitro experiments, and TRP channel findings in particular have shown inconsistent replication between species. A mechanism that looks clean in a cell culture dish does not always hold up the same way in a living rodent, and a rodent finding does not always hold up in a human. The lipophilicity argument is the most solid piece of the puzzle, since it is a measurable chemical property rather than an inferred biological effect, but it only explains why myrcene could reach the brain quickly, not exactly what it does once it gets there.

Human Evidence and Safety: Clinical Data, the Driving Study, and the Toxicology Debate

This is where the evidence base gets thinnest and the safety questions get most practically relevant. Separating what has actually been tested in people from what has only been shown in rodents matters more here than almost anywhere else in the myrcene conversation.

The most rigorous human data available comes from a 2023 pilot study. A double-blind, placebo-controlled, crossover study gave healthy volunteers 15 milligrams of pure beta-myrcene and tested their performance on a driving simulator against a placebo condition. The results showed statistically significant reductions in speed control and more divided-attention errors under myrcene compared to placebo.

A small but controlled human trial found that an isolated dose of beta-myrcene measurably impaired driving-related performance, including speed control and divided attention, compared with placebo.

This is a small study, with only 10 participants, so it should not be read as definitive proof that every myrcene-containing product impairs driving at every dose. But it is also the kind of controlled, double-blind evidence that is rare in cannabis terpene research, and it directly contradicts the casual assumption that terpenes are effects-neutral flavor compounds with no standalone impact on cognition or motor skills.

Beyond the driving study, human data on myrcene is limited to a handful of very small inhalation and EEG studies. One study with roughly five participants had them inhale cannabis essential oil containing 22.9% myrcene and reported increased theta and alpha EEG activity along with subjective reports of relaxation, according to the Frontiers review summarizing this research. That is a suggestive finding for the relaxation claim, but a sample size that small cannot establish a reliable effect size or rule out individual variation.

On the safety side, the controversial piece of the literature is older rodent gavage toxicology work. NTP-style long-term studies that force-fed rats and mice very high oral doses of beta-myrcene over extended periods reported increased incidence of renal and hepatic tumors. These findings drove myrcene’s history with food safety regulators and still show up in alarmist consumer content about the compound.

The important context, laid out in a regulatory and toxicology review of myrcene’s profile, is that the doses used in those rodent studies were orders of magnitude higher than typical human exposure from food flavoring or cannabis consumption, and the specific tumor mechanisms involved (including certain kidney pathology patterns seen mainly in male rats) are considered poorly predictive of human risk by toxicologists. The review also notes that myrcene’s removal from some food additive lists reflected legal and regulatory procedure rather than new evidence of human harm, and that typical dietary exposure sits far below the doses used in the rodent experiments. The takeaway is not that myrcene is risk-free, but that the rodent cancer data, while real, does not translate cleanly into a human cancer warning at the exposure levels most consumers encounter.

How Myrcene Appears in Products and Reading COAs for Myrcene Content

If you want to make an informed choice about myrcene exposure, the certificate of analysis (COA) attached to a product is your most reliable source, far more useful than a strain name alone.

Here is what to look for and why it matters:

  1. Find the terpene panel, not just the cannabinoid panel. Many COAs separate cannabinoid testing (THC, CBD, and related compounds) from terpene testing, and myrcene will be listed by name within the terpene section if that batch was tested for it.
  2. Check the unit of measurement. Terpene content is usually reported either in milligrams per gram (mg/g) or as a percentage by weight, and the two can look very different at a glance even when they represent similar concentrations, so convert mentally before comparing products.
  3. Compare against typical ranges by product type. Flower generally shows terpene totals in the low single-digit percentages, concentrates can show higher relative terpene density depending on extraction method, and isolated terpene additives will list a much higher, near-pure concentration.
  4. Expect batch variability even within the same strain name. A new harvest of a familiar strain can test meaningfully higher or lower in myrcene than the last batch you bought, which is why checking the specific COA for the product in hand, rather than relying on memory of a past experience, gives a more accurate picture.
  5. Consider consumption method and volatility. Myrcene has a relatively low boiling point compared to some other terpenes, which means vaping at lower temperatures may preserve more of it than smoking, while oral products like edibles expose you to whatever survived extraction and manufacturing rather than what was in the original plant.

Our cannabis terpenes guide walks through terpene chemistry and vaping temperature considerations in more depth if you want to understand how heat affects which compounds actually reach you.

Pro Tip: Before buying based on a myrcene claim, pull up the batch-specific COA rather than trusting the strain name, since terpene content can shift meaningfully between harvests.

Practical Implications: Dosing, Interactions, and Impairment

Translating the research into day-to-day decisions means separating what is reasonably well supported from what is still speculative, and erring toward caution on the parts that affect safety.

Onset and duration vary significantly by consumption method, and these differences matter more for a sedating compound like myrcene than for most other terpenes:

  • Inhalation (smoking or vaping) tends to produce the fastest onset, often within minutes, because the compound reaches the bloodstream through the lungs almost immediately.
  • Oral ingestion (edibles) produces a delayed and less predictable onset, generally estimated in the range of 30 to 120 minutes, since the compound has to pass through digestion and liver metabolism first.
  • Topical application produces localized effects with minimal systemic absorption in most cases, which is relevant if you are trying to avoid central nervous system effects altogether.

Given the driving-simulator findings described earlier, the most actionable safety guidance is straightforward: do not drive or operate machinery after trying a new high-myrcene product until you understand your own response to it. That pilot study showed measurable impairment from an isolated dose in healthy volunteers, and there is no reason to assume a whole-plant product with a similar myrcene load would behave differently.

Interaction caution deserves equal weight. Because myrcene may affect CYP enzyme activity and has shown additive sedative effects in combination with other sedating compounds in animal studies, combining high-myrcene products with alcohol, benzodiazepines, or opioid medications carries a plausible risk of amplified sedation. Anyone on prescription medications metabolized by CYP enzymes should discuss cannabis use with a healthcare provider rather than assuming terpene content is irrelevant to their treatment.

Pro Tip: Start with a small amount of any new high-myrcene product, try it somewhere you do not need to drive afterward, and wait at least a few hours before judging the full effect, especially with edibles.

Keys set aside before driving after cannabis use

If you take prescription medications, have a medical condition, or are otherwise cautious about sedation, talk to a healthcare provider before using a new cannabis product, regardless of how it is marketed on terpene content alone.

Research Gaps and What Better Human Studies Should Do

The myrcene literature has a consistent shape: plausible mechanisms, encouraging animal data, and a near-total absence of large, well-controlled human trials. Closing that gap would change how confidently anyone can make claims about this compound.

The priority gaps are specific enough to describe:

  • Dose-response data in humans. No published trial has mapped out how different doses of isolated myrcene affect sedation, pain, or mood in a graded way across a meaningful sample size.
  • Isolated terpene versus whole-plant comparisons. Almost all consumer claims assume myrcene behaves the same whether isolated or embedded in a full cannabis matrix with THC, CBD, and other terpenes, an assumption no study has directly tested.
  • Pharmacokinetic and pharmacodynamic data. Reliable human data on how quickly myrcene is absorbed, metabolized, and cleared after realistic product use (not isolated capsule doses) remains sparse.
  • Larger randomized controlled trials with clinical endpoints. Pain relief, sleep quality, and anxiety reduction all need trials with real clinical outcome measures, not just subjective relaxation reports from a handful of participants.

The most useful next studies would likely include a double-blind crossover trial comparing high-myrcene and low-myrcene cannabis strains matched for THC content, which would isolate the terpene’s contribution from the cannabinoid effect, and pharmacokinetic studies that sample blood plasma after typical product use rather than isolated lab doses. Until that kind of data exists, both consumer guidance and product labeling will continue to rest more on biological plausibility than on confirmed clinical effect.

Our Take on Lab Testing, COAs, and Terpene Education

We built our service around the idea that cannabis consumers deserve the same transparency that any other regulated consumer product provides. Every item we offer comes through a licensed supply chain with verifiable lab results attached, which means the batch variability discussed throughout this article is something you can actually check rather than guess about.

For a terpene like myrcene, where the honest answer to most questions is “the human evidence is still limited,” having access to a real COA matters more than trusting a strain name or a dispensary description. Our cannabis strain guide lets you look at terpene profiles alongside lab data before you order, so if you are specifically trying to understand your own response to a higher-myrcene product, you can start with a known quantity instead of a marketing claim.

We would rather you make that decision with real information in front of you, including the caution this article raises about driving and sedative interactions, than order blind. If you have questions about a specific batch’s COA, customer service can assist before your order arrives.

— Jake

Order Lab-Tested, Terpene-Labeled Products in Alameda County

Greenonthegodelivery

We deliver licensed, lab-tested cannabis the same day across Alameda County, with a menu built around batch consistency rather than guesswork, so when you want a specific terpene profile, you can find one backed by real lab data.

If you already know you want to try a higher-myrcene flower or pre-roll based on what you have read here, the fastest path is to order online and have it delivered same day, with the COA available for the batch you receive.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What does myrcene make you feel like?

Myrcene is most commonly associated with a relaxed, sedated feeling, though this is based mainly on animal studies and one small human inhalation study reporting relaxation and EEG changes consistent with a calmer state. A 2023 driving-simulator pilot study also found that an isolated dose affected attention and speed control, which points to a real measurable effect rather than a purely subjective one.

Is myrcene banned?

Myrcene itself is not broadly banned as a compound; it occurs naturally in many foods, including hops and mangoes, and is used as a flavoring agent. Its regulatory history involves specific food-additive listing questions tied to older rodent toxicology studies, discussed in a review of its biological and toxicological profile, rather than a blanket prohibition on the molecule.

What is the mother of all terpenes?

Myrcene is sometimes informally called the “mother of all terpenes” because it is thought to be a biosynthetic precursor that plants use to build other terpene compounds, and because it is so prevalent across cannabis cultivars. This nickname reflects its structural role and abundance rather than a specific clinical designation.

What strain is highest in myrcene?

Myrcene content varies by batch and testing lab rather than being a fixed trait of any single strain name, so the only reliable way to identify a high-myrcene product is to check the certificate of analysis for that specific batch. Our cannabis strain guide lets you compare terpene profiles alongside lab data to find options that test higher in myrcene.

Does myrcene make you sleepy?

Rodent studies have shown myrcene prolonging sedative-drug-induced sleep time, and a small human inhalation study reported subjective relaxation, which together suggest a plausible sedative effect. However, the evidence for a direct sleep-inducing effect in humans at typical consumption levels remains limited, and individual responses vary considerably.

Sources

Ready to order?

Licensed, same-day cannabis delivery across Oakland, Berkeley, Fremont and all of Alameda County.

Order Online